The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials
Rehovot, Israel – January 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127
Rehovot, Israel – November 12, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today positive preliminary results from recently completed animal studies in its immuno-oncology program,
The company has in-licensed IP and knowhow generated by Prof. Ada E. Yonath, Nobel Prize winner, who will advise Biomica on the program
Rehovot, Israel – October 23, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
Aims to augment current cancer therapies by altering patients’ gut microbiome to improve response
Rehovot, Israel – April 16, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
